Dementia and Alzheimer Disease

Here's what is coming soon to NeurologyLive.

The professor from the Universite de Sherbrooke discusses how his recent study supports the concept of brain energy rescue.

The director of the Montefiore Einstein Center for the Aging Brain discussed the advantages of non-invasive brain stimulation and what has been previously observed in patients with Alzheimer disease.

Researchers will aim to create and validate a risk calculator and screening tool to identify and test individuals with high risk of cognitive decline.

Neurology News Network for the week ending November 14, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 13, 2020.

The study authors noted that dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.

The Cleveland Clinic researcher discussed the unknowns about Parkinson disease dementia and what has been previously observed in clinical studies.

Here's what is coming soon to NeurologyLive.

There is no evidence yet that SARS-CoV-2 can pass the blood-brain barrier, though its effects on the barrier may be intensified in those with dementia.

Neurology News Network for the week ending November 7, 2020.

Biogen’s investigational Alzheimer disease treatment is currently under review with a Prescription Drug User Fee Act target action date of March 7, 2021, if not earlier.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 6, 2020.

Based on data from a study of 686 patients with subjective cognitive impairment or dementia, the PrecivityAD blood test correctly identified brain amyloid plaque status in 86% of the patients.

CND Life Science’s Syn-One test marks the next step in synucleinopathy detection by offering a quick and minimally invasive procedure.

The researchers aim to fill the void of approved treatments for mild cognitive impairment, showing the potential of brain energy rescue strategies in this patient population.

Joe Verghese, MBBS, MS, details the research being conducted on motoric cognitive risk syndrome and noninvasive brain stimulation in Alzheimer disease.

A recently published critique of aducanumab's trial results calls for a third and definitive phase 3 study of the investigational agent, which is awaiting a decision from the FDA.

Contrary to prior findings, no evidence was found to support a protective association between leisure activity and risk of dementia.

In addition to recommendations for Alzheimer disease screening, the guidelines also covered stroke risk-related assessments which should be conducted for those with Down syndrome.

The findings suggest that poor speech-in-noise hearing may be an early marker of underlying dementia processes.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 30, 2020.

The researchers concluded that the effect of lowered blood pressure might not be evident in specific domains of cognitive function, but instead distributed across multiple domains.

The company is planning a pivotal trial of blarcamesine in Parkinson disease dementia after submitting results of the phase 2 study to the FDA for regulatory guidance.

The director of the Montefiore Einstein Center for the Aging Brain detailed the symptoms of motoric cognitive risk syndrome and how they compare to more typical mild cognitive impairment.

Constantino Iadecola, MD, discusses the interaction of vascular risk factors and the shortcomings of our current clinical approach to Alzheimer disease.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 23, 2020.

The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.